US20110301234A1 - Formulations of ladostigil tartrate - Google Patents
Formulations of ladostigil tartrate Download PDFInfo
- Publication number
- US20110301234A1 US20110301234A1 US13/211,721 US201113211721A US2011301234A1 US 20110301234 A1 US20110301234 A1 US 20110301234A1 US 201113211721 A US201113211721 A US 201113211721A US 2011301234 A1 US2011301234 A1 US 2011301234A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- methyl
- propargyl
- aminoindan
- carbamoyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000009472 formulation Methods 0.000 title description 45
- PRLVBVAJMQZMJN-OGOSNNLPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;[(3r)-3-(prop-2-ynylamino)-2,3-dihydro-1h-inden-5-yl] n-ethyl-n-methylcarbamate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1.CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1 PRLVBVAJMQZMJN-OGOSNNLPSA-N 0.000 title description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 55
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 27
- 229940095064 tartrate Drugs 0.000 claims abstract description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 230000036470 plasma concentration Effects 0.000 claims abstract description 18
- 210000002381 plasma Anatomy 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000007787 solid Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 25
- 235000021355 Stearic acid Nutrition 0.000 claims description 17
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 17
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 17
- 239000008117 stearic acid Substances 0.000 claims description 17
- 239000000314 lubricant Substances 0.000 claims description 16
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 13
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000000454 talc Substances 0.000 claims description 12
- 229910052623 talc Inorganic materials 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 238000005550 wet granulation Methods 0.000 claims description 8
- -1 N-ethyl-carbamoyloxy Chemical group 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 16
- 229920002472 Starch Polymers 0.000 description 15
- 239000008107 starch Substances 0.000 description 15
- 229940032147 starch Drugs 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- 229930195725 Mannitol Natural products 0.000 description 14
- 239000000594 mannitol Substances 0.000 description 14
- 235000010355 mannitol Nutrition 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 229950008812 ladostigil Drugs 0.000 description 13
- LHXOCOHMBFOVJS-OAHLLOKOSA-N Ladostigil Chemical compound CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1 LHXOCOHMBFOVJS-OAHLLOKOSA-N 0.000 description 12
- 239000012535 impurity Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 5
- 238000005567 liquid scintillation counting Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HTSFGBRWMBRBLU-UHFFFAOYSA-N (3-amino-2,3-dihydro-1h-inden-5-yl) n-ethyl-n-methylcarbamate Chemical compound CCN(C)C(=O)OC1=CC=C2CCC(N)C2=C1 HTSFGBRWMBRBLU-UHFFFAOYSA-N 0.000 description 1
- DEXRDMVBOUGLGT-UHFFFAOYSA-N (3-oxo-1,2-dihydroinden-5-yl) n-ethyl-n-methylcarbamate Chemical compound CCN(C)C(=O)OC1=CC=C2CCC(=O)C2=C1 DEXRDMVBOUGLGT-UHFFFAOYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 0 [1*]N([2*])C1CCC2=CC=CC=C21.[3*]N([4*])C(=[Y])OCC Chemical compound [1*]N([2*])C1CCC2=CC=CC=C21.[3*]N([4*])C(=[Y])OCC 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012628 flowing agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to formulations of tartrate salt of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan.
- PCT Application Publication No. WO98/27055 discloses indanylamine and aminotetralin derivative compounds, such as those of Formula I below, which are useful to treat depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementias.
- the indanylamine derivatives disclosed have been show to have biological effects in animal models of neurological disease.
- PCT Application Publication No. WO98/27055 discloses methods for preparation of the indanylamine derivative compounds.
- b is 1 or 2; m is 0-3; Y is O or S; X is halo; R 1 is hydrogen or C 1-4 alkyl; R 2 is hydrogen, C 1-4 alkyl, or optionally substituted propargyl; and R 3 and R 4 are each independently hydrogen, C 1-8 alkyl, C 6-12 aryl, C 6-12 aralkyl, each optionally halo substituted.
- R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan also known as (3R)-3-(prop-2-ynylamino)-2,3,-ethylmethylcarbamate
- 3R -3-(prop-2-ynylamino)-2,3,-ethylmethylcarbamate
- salts are disclosed, including the 1 ⁇ 2 L-tartrate salt. This salt has been given the nonproprietary name ladostigil tartrate. Its CAS registry number is 209394-46-7.
- compositions i.e., formulations, comprising ladostigil tartrate suited for storage and desired pharmacokinetics have not been previously disclosed.
- the subject invention provides a formulation comprising tartrate salt crystals of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate, at least one pharmaceutically acceptable excipient and no more than 0.5% by weight of the composition of magnesium stearate.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate, at least one pharmaceutically acceptable excipient and no more than 1.5% by weight of the composition of sodium stearyl fumarate.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate and a pharmaceutically acceptable carrier, formulated so as to provide upon administration to a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
- the subject invention also provides a method for inducing in a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL after one administration, comprising administering orally to the human subject a solid pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate and a pharmaceutically acceptable carrier so as to induce in the subject the blood plasma concentration.
- the subject invention provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water.
- the pharmaceutical composition comprises 2-5% water.
- the pharmaceutical composition comprises 1-5% water.
- the pharmaceutical composition comprises 1.5-4% water.
- the pharmaceutical composition comprises 2-3.5% water.
- the pharmaceutical composition comprises 2-3.5% water.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate, at least one pharmaceutically acceptable excipient and no more than 0.5% by weight of the composition of magnesium stearate.
- the pharmaceutical composition is free of magnesium stearate.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate, at least one pharmaceutically acceptable excipient and no more than 1.5% by weight of the composition of sodium stearyl fumarate.
- the composition comprises no more than 0.5% by weight of the composition of sodium stearyl fumarate.
- the pharmaceutical composition is free of sodium stearyl fumarate.
- no more than 0.5% by weight of the composition is magnesium stearate.
- the pharmaceutical composition is free of magnesium stearate and of stearic acid.
- no more than 0.5% by weight of the composition is sodium stearyl fumarate.
- the pharmaceutical composition is free of sodium stearyl fumarate.
- no more than 0.5% by weight of the composition is stearic acid.
- the pharmaceutical composition is free of stearic acid.
- At least one pharmaceutically acceptable excipient is a first filler, a second filler, a disintegrant, a flow agent, a binder and a lubricant.
- the lubricant is talc.
- talc is present in an amount of up to 4% by weight of the composition.
- the lubricant further comprises stearic acid.
- the stearic acid is present in an amount of up to 2% by weight of the composition.
- the lubricant is stearic acid.
- the pharmaceutical composition is free of talc.
- the pharmaceutical composition is free of stearic acid.
- the first filler is mannitol present in an amount of 6 to 16% by weight
- the second filler is mannitol granulate present in an amount of 0 to 56% by weight
- the disintegrant is starch present in an amount of 15 to 38% by weight
- the flow agent is colloidal silicon dioxide present in an amount of 1 to 2% by weight
- the binder is polyvinylpyrolidone present in an amount of 3 to 8% by weight.
- the first filler is mannitol present in an amount of 6.6% by weight
- the second filler is mannitol granulate present in an amount of 56.1% by weight
- the disintegrant is starch present in an amount of 15.2% by weight
- the flow agent is colloidal silicon dioxide present in an amount of 0.9% by weight
- the binder is polyvinylpyrolidone present in an amount of 3.4% by weight
- the lubricant is talc in an amount of 3.8% by weight and stearic acid in an amount of 1.9% by weight.
- the first filler is mannitol present in an amount of 16.4% by weight
- the disintegrant is starch present in an amount of 37.5% by weight
- the flow agent is colloidal silicon dioxide present in an amount of 2.1% by weight
- the binder is polyvinylpyrolidone present in an amount of 8.4% by weight
- the lubricant is talc in an amount of 3.7% by weight and stearic acid in an amount of 1.9% by weight.
- the pharmaceutical is in the form of tablets, capsules, pills, powders, or granules.
- the pharmaceutical composition is in tablet form.
- the pharmaceutical composition is in capsule form.
- the pharmaceutical composition upon administration to a human subject provides a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate and a pharmaceutically acceptable carrier, formulated so as to provide upon administration to a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
- the pharmaceutical composition is formulated so as to provide in the human subject a blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.01 nmol/mL twelve hours after dosing.
- the pharmaceutical composition is formulated so as to provide in the human subject a blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 1.88 nmol/mL.
- the pharmaceutical composition is formulated so as to provide a monoamine oxidase B inhibition of 59%-91% upon administration to a human subject as determined by liquid scintillation counting.
- the pharmaceutical composition is formulated so as to provide a monoamine oxidase B inhibition of 75% upon administration to a human subject as determined by liquid scintillation counting.
- the pharmaceutical composition is formulated so as to provide a 28%-86% decrease of 3,4-dihydroxyphenylglycol plasma concentration upon administration to a human subject as determined by liquid scintillation counting.
- the pharmaceutical composition is formulated so as to provide a 57% decrease of 3,4-dihydroxyphenylglycol plasma concentration upon administration to a human subject as determined by liquid scintillation counting.
- the pharmaceutical composition administered comprises 25-105 mg R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate.
- the subject invention also provides a method for inducing in a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL after one administration, comprising administering orally to the human subject a solid pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate and a pharmaceutically acceptable carrier so as to induce in the subject the blood plasma concentration.
- the blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 12 hours after administration is at least 0.01 nmol/mL.
- the maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan is 1.88 nmol/mL.
- the pharmaceutical composition administered comprises 25-105 mg R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 1 ⁇ 2 tartrate.
- the subject invention also provides a method of treating a subject afflicted with Parkinson's disease, Alzheimer's disease or dementia, depression or a neurological disorder comprising administering to the subject the pharmaceutical composition as described herein.
- the subject is afflicted with a neurological disorder and the neurological disorder is epilepsy, narcolepsy, amyotrophic lateral sclerosis (“ALS”), memory disorders, panic, post-traumatic stress disorder (“PTSD”), sexual dysfunction, attention deficit and hyperactivity syndrome (“ADHD”), attention deficit disorder, or Tourette's syndrome.
- the neurological disorder is epilepsy, narcolepsy, amyotrophic lateral sclerosis (“ALS”), memory disorders, panic, post-traumatic stress disorder (“PTSD”), sexual dysfunction, attention deficit and hyperactivity syndrome (“ADHD”), attention deficit disorder, or Tourette's syndrome.
- the subject is afflicted with dementia and the dementia is static dementia, Alzheimer's-type dementia, senile dementia, presenile dementia, progressive dementia, vascular dementia or Lewy body dementia.
- the subject is afflicted with Alzheimer's disease.
- the subject is afflicted with Parkinson's disease.
- the subject invention also provides a process for making the pharmaceutical composition comprising the step of wet granulation.
- the process comprises the step of wet granulation in the absence of water addition.
- the step of wet granulation is performed in the presence of isopropanol.
- the process is performed in the absence of ethanol.
- a “pharmaceutically acceptable” excipient is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- a dosage unit may comprise a single compound or mixtures of compounds thereof.
- a dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, and granules.
- the drug substance can be administered in admixture with suitable pharmaceutical diluents, extenders, excipients, or carriers (collectively referred to herein as a pharmaceutically acceptable excipient) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
- a pharmaceutically acceptable excipient suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
- the unit will be in a form suitable for oral administration.
- the drug substance can be administered alone but are generally mixed with a pharmaceutically acceptable excipient, and co-administered in the form of a tablet or capsule, liposome, or as an agglomerated powder.
- Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders.
- Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
- the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert excipient such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like.
- Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
- Ladostigil tartrate can be prepared following the disclosure of PCT International Application Publication No. WO98/27055.
- ladostigil tartrate can be prepared as indicated in the following example: In a 250 liter reactor, a solution of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan (8.3 kg) in isopropanol (52.4 liters) was heated to 60-65° C. The solution was seeded with 50 g of ladostigil tartrate and a solution of L-tartaric acid (2.4 kg) in isopropanol (38.5 liters) was added dropwise over 2.5-3.5 hours. The mixture was maintained at 60-65° C. for 4-15 hr and was then gradually cooled to 0-5° C.
- the product was collected in a filter drier and was washed with cold isopropanol (77 liters).
- the wet material was dried in a filter drier in three stages until moisture content was less than 0.5%.
- the product was dried by static drying for 4 hours at 50-60° C. and under vacuum of less than 50 mbar.
- the product was dried while being stirred for 2 hours at 50-60° C. and under vacuum of less than 50 mbar.
- the product was dried while being stirred for 2 hours at 78-82° C. and under vacuum of less than 50 mbar.
- the amount of ladostigil tartrate and mannitol remains constant, but the ratio between the two changes; the amount of the other excipients remains constant.
- the proportional formulation is double the formulation of the 25 mg pseudo-proportional formulation.
- Tablets using formulation O were manufactured using direct compression. On a small scale, the tablets using formulation O were manufactured without sticking problems. However, on a larger scale, and when other batches of ladostigil tartrate with different particle size distributions were used, there were sticking problems in the tableting process.
- formulations P, Q and R were manufactured using dry granulation, and using two different lubricants. This eliminated some of the sticking problems.
- Formulation Q was the most stable, apparently due to the lack of sodium stearyl fumarate as a lubricant. Accordingly, optimization of double weight formulation Q was performed to increase compressibility and stability, and the results are shown in Table 4:
- Formulations R1, Y, BB and CC were stable under accelerated conditions.
- a flow problem resulted, however, due to large variability in particle size distribution, resulting in a change in the crystallization method of ladostigil tartrate.
- the manufacturing process was changed from the dry granulation process to a wet-granulation process as a result of the flow problem with the active ingredient.
- Water and ethanol are the two most common agents used in wet granulation.
- Granulation experiments were first performed with water. The appearance of the formulations containing those granulates became creamy to brownish after 1 day at 55° C., which indicated that ladostigil tartrate was unstable in the presence of water. Moreover, ladostigil tartrate was found to be incompatible with ethanol. Therefore, granulation experiments based on the CC formulation were performed with isopropanol.
- R-CAI and CIONE are acronyms for the following impurities: Ethyl-methyl-carbamic acid 3-amino-indan-5-yl ester and Ethyl-methyl-carbamic acid 3-oxo-indan-5-yl ester, respectively.
- More binder (PVP) was later added in order to improve structure and flowing properties after granulation.
- Capsules were made from the excipients in Table 9. The capsules were determined to be stable at RT for 21 months, and at 30° C. for 12 months.
- Ladostigil Tartrate to Alzheimer's Disease Patients 8 patients, 7 female and 1 male, ages 62-81 with a median age of 68 and above with diagnosis of probable Alzheimer's disease according to DSM-IV (290.00 or 290.10) and NINCDS-ADRDA criteria were administered ladostigil tartrate as formulated in Table 9 according to the following schedule: Week 1: 70 mg (50+20) once daily. Week 2: 70 mg (50+20) twice daily. Week 3-Week 9: 100 mg (50*2) twice daily.
- Pharmacokinetic analysis was performed on Week 4 (maintenance analysis) and on Week 9 (termination analysis).
- M maintenance analysis
- T termination analysis
- MAO-B Monoamine oxidase B
- DHPG 3,4-dihydroxyphenylglycol
- the decrease in DHPG concentration in the six patients was determined.
- the average decrease in DHPG concentration was determined to be 57% with a standard deviation of 29.
- the data show that the analytes were present at pre-dose (which corresponds to 12 hours after the previous dose) both at maintenance and at termination analyses.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a continuation of application Ser. No. 11/361,379 filed Feb. 24, 2006, which in turn claims the benefit of U.S. Provisional Application No. 60/656,477, filed Feb. 24, 2005. The entire content of each earlier application is hereby expressly incorporated by reference.
- Throughout this application various publications, published patent applications, and published patents are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
- The present invention relates to formulations of tartrate salt of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan.
- PCT Application Publication No. WO98/27055 discloses indanylamine and aminotetralin derivative compounds, such as those of Formula I below, which are useful to treat depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementias. The indanylamine derivatives disclosed have been show to have biological effects in animal models of neurological disease. In addition, PCT Application Publication No. WO98/27055 discloses methods for preparation of the indanylamine derivative compounds.
- wherein b is 1 or 2; m is 0-3; Y is O or S; X is halo; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted.
- R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan, also known as (3R)-3-(prop-2-ynylamino)-2,3,-ethylmethylcarbamate, is disclosed in PCT Application Publication No. WO98/27055, specifically compound 76 in Table 5. In addition, salts are disclosed, including the ½ L-tartrate salt. This salt has been given the nonproprietary name ladostigil tartrate. Its CAS registry number is 209394-46-7.
- Specific pharmaceutical compositions, i.e., formulations, comprising ladostigil tartrate suited for storage and desired pharmacokinetics have not been previously disclosed.
- The subject invention provides a formulation comprising tartrate salt crystals of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and no more than 0.5% by weight of the composition of magnesium stearate.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and no more than 1.5% by weight of the composition of sodium stearyl fumarate.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate and a pharmaceutically acceptable carrier, formulated so as to provide upon administration to a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
- The subject invention also provides a method for inducing in a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL after one administration, comprising administering orally to the human subject a solid pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate and a pharmaceutically acceptable carrier so as to induce in the subject the blood plasma concentration.
- The subject invention provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water.
- In an embodiment, the pharmaceutical composition comprises 2-5% water.
- In a further embodiment, the pharmaceutical composition comprises 1-5% water.
- In a further embodiment, the pharmaceutical composition comprises 1.5-4% water.
- In yet a further embodiment, the pharmaceutical composition comprises 2-3.5% water.
- In yet a further embodiment, the pharmaceutical composition comprises 2-3.5% water.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and no more than 0.5% by weight of the composition of magnesium stearate.
- In an embodiment, the pharmaceutical composition is free of magnesium stearate.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and no more than 1.5% by weight of the composition of sodium stearyl fumarate.
- In an embodiment, the composition comprises no more than 0.5% by weight of the composition of sodium stearyl fumarate.
- In another embodiment, the pharmaceutical composition is free of sodium stearyl fumarate.
- In another embodiment, no more than 0.5% by weight of the composition is magnesium stearate.
- In another embodiment, the pharmaceutical composition is free of magnesium stearate and of stearic acid.
- In another embodiment, no more than 0.5% by weight of the composition is sodium stearyl fumarate.
- In another embodiment, the pharmaceutical composition is free of sodium stearyl fumarate.
- In another embodiment, no more than 0.5% by weight of the composition is stearic acid.
- In another embodiment, the pharmaceutical composition is free of stearic acid.
- In yet another embodiment, at least one pharmaceutically acceptable excipient is a first filler, a second filler, a disintegrant, a flow agent, a binder and a lubricant.
- In yet another embodiment, the lubricant is talc.
- In yet another embodiment, talc is present in an amount of up to 4% by weight of the composition.
- In yet another embodiment, the lubricant further comprises stearic acid.
- In yet another embodiment, the stearic acid is present in an amount of up to 2% by weight of the composition.
- In yet another embodiment, the lubricant is stearic acid.
- In yet another embodiment, the pharmaceutical composition is free of talc.
- In yet another embodiment, the pharmaceutical composition is free of stearic acid.
- In a further embodiment, the first filler is mannitol present in an amount of 6 to 16% by weight, the second filler is mannitol granulate present in an amount of 0 to 56% by weight, the disintegrant is starch present in an amount of 15 to 38% by weight, the flow agent is colloidal silicon dioxide present in an amount of 1 to 2% by weight, and the binder is polyvinylpyrolidone present in an amount of 3 to 8% by weight.
- In yet a further embodiment, the first filler is mannitol present in an amount of 6.6% by weight, the second filler is mannitol granulate present in an amount of 56.1% by weight, the disintegrant is starch present in an amount of 15.2% by weight, the flow agent is colloidal silicon dioxide present in an amount of 0.9% by weight, the binder is polyvinylpyrolidone present in an amount of 3.4% by weight, and the lubricant is talc in an amount of 3.8% by weight and stearic acid in an amount of 1.9% by weight.
- In yet a further embodiment, the first filler is mannitol present in an amount of 16.4% by weight, the disintegrant is starch present in an amount of 37.5% by weight, the flow agent is colloidal silicon dioxide present in an amount of 2.1% by weight, the binder is polyvinylpyrolidone present in an amount of 8.4% by weight, and the lubricant is talc in an amount of 3.7% by weight and stearic acid in an amount of 1.9% by weight.
- In yet a further embodiment, the pharmaceutical is in the form of tablets, capsules, pills, powders, or granules.
- In yet a further embodiment, the pharmaceutical composition is in tablet form.
- In yet a further embodiment, the pharmaceutical composition is in capsule form.
- In yet a further embodiment, the pharmaceutical composition upon administration to a human subject provides a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
- The subject invention also provides a pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate and a pharmaceutically acceptable carrier, formulated so as to provide upon administration to a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
- In an embodiment, the pharmaceutical composition is formulated so as to provide in the human subject a blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.01 nmol/mL twelve hours after dosing.
- In another embodiment, the pharmaceutical composition is formulated so as to provide in the human subject a blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 1.88 nmol/mL.
- In another embodiment, the pharmaceutical composition is formulated so as to provide a monoamine oxidase B inhibition of 59%-91% upon administration to a human subject as determined by liquid scintillation counting.
- In yet another embodiment, the pharmaceutical composition is formulated so as to provide a monoamine oxidase B inhibition of 75% upon administration to a human subject as determined by liquid scintillation counting.
- In a further embodiment, the pharmaceutical composition is formulated so as to provide a 28%-86% decrease of 3,4-dihydroxyphenylglycol plasma concentration upon administration to a human subject as determined by liquid scintillation counting.
- In a further embodiment, the pharmaceutical composition is formulated so as to provide a 57% decrease of 3,4-dihydroxyphenylglycol plasma concentration upon administration to a human subject as determined by liquid scintillation counting.
- In yet a further embodiment, the pharmaceutical composition administered comprises 25-105 mg R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate.
- The subject invention also provides a method for inducing in a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL after one administration, comprising administering orally to the human subject a solid pharmaceutical composition comprising R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate and a pharmaceutically acceptable carrier so as to induce in the subject the blood plasma concentration.
- In an embodiment of the method, the blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan 12 hours after administration is at least 0.01 nmol/mL.
- In another embodiment of the method, the maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan is 1.88 nmol/mL.
- In another embodiment of the method, the pharmaceutical composition administered comprises 25-105 mg R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate.
- The subject invention also provides a method of treating a subject afflicted with Parkinson's disease, Alzheimer's disease or dementia, depression or a neurological disorder comprising administering to the subject the pharmaceutical composition as described herein.
- In an embodiment, the subject is afflicted with a neurological disorder and the neurological disorder is epilepsy, narcolepsy, amyotrophic lateral sclerosis (“ALS”), memory disorders, panic, post-traumatic stress disorder (“PTSD”), sexual dysfunction, attention deficit and hyperactivity syndrome (“ADHD”), attention deficit disorder, or Tourette's syndrome.
- In another embodiment, the subject is afflicted with dementia and the dementia is static dementia, Alzheimer's-type dementia, senile dementia, presenile dementia, progressive dementia, vascular dementia or Lewy body dementia.
- In another embodiment, the subject is afflicted with Alzheimer's disease.
- In another embodiment, the subject is afflicted with Parkinson's disease.
- The subject invention also provides a process for making the pharmaceutical composition comprising the step of wet granulation. In an embodiment, the process comprises the step of wet granulation in the absence of water addition.
- In a further embodiment, the step of wet granulation is performed in the presence of isopropanol.
- In yet a further embodiment, the process is performed in the absence of ethanol.
- As used herein, a “pharmaceutically acceptable” excipient is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- A dosage unit may comprise a single compound or mixtures of compounds thereof. A dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, and granules.
- The drug substance can be administered in admixture with suitable pharmaceutical diluents, extenders, excipients, or carriers (collectively referred to herein as a pharmaceutically acceptable excipient) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices. The unit will be in a form suitable for oral administration. The drug substance can be administered alone but are generally mixed with a pharmaceutically acceptable excipient, and co-administered in the form of a tablet or capsule, liposome, or as an agglomerated powder. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders.
- Specific examples of pharmaceutically acceptable excipients that may be used to formulate oral dosage forms of the present invention are described, e.g., in U.S. Pat. No. 3,903,297 to Robert, issued Sep. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described-in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.).
- Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. For instance, for oral administration in the dosage unit form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert excipient such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
- Ladostigil tartrate can be prepared following the disclosure of PCT International Application Publication No. WO98/27055.
- Alternatively, ladostigil tartrate can be prepared as indicated in the following example: In a 250 liter reactor, a solution of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan (8.3 kg) in isopropanol (52.4 liters) was heated to 60-65° C. The solution was seeded with 50 g of ladostigil tartrate and a solution of L-tartaric acid (2.4 kg) in isopropanol (38.5 liters) was added dropwise over 2.5-3.5 hours. The mixture was maintained at 60-65° C. for 4-15 hr and was then gradually cooled to 0-5° C. The product was collected in a filter drier and was washed with cold isopropanol (77 liters). The wet material was dried in a filter drier in three stages until moisture content was less than 0.5%. In the first drying stage, the product was dried by static drying for 4 hours at 50-60° C. and under vacuum of less than 50 mbar. In the second drying stage, the product was dried while being stirred for 2 hours at 50-60° C. and under vacuum of less than 50 mbar. In the third drying stage the product was dried while being stirred for 2 hours at 78-82° C. and under vacuum of less than 50 mbar.
- This alternative process, which can be performed without the seeding step, is better suited for use in a pilot scale and a production scale than a method that follows PCT Application Publication No. WO98/27055. Ladostigil tartrate prepared using this alternative process results in crystals having bulk density of 0.22-0.29 and tapped density of 0.38-0.54 g/ml.
- Regardless of how the crystalline ladostigil tartrate was prepared, initial attempts at formulating ladostigil tartrate encountered problems in terms of flowability and compressibility. As a result, improved formulations of ladostigil tartrate are disclosed.
- The first formulations of ladostigil tartrate, prepared by dry granulation, are shown in Table 1:
-
TABLE 1 First Formulations Pseudo-Proportional Proportional Component (mg/tablet) (mg/tablet) (mg) 5 mg 20 mg 25 mg 50 mg Function Ladostigil 6.4 25.68 32.0 64.0 Drug Tartrate Substance Mannitol 45.6 26.4 20.0 40.0 Filler Pregelatinized 40.0 40.0 40.0 80.0 Disintegrant Starch (STA-RX 1500) SYLOID 244FP 4.5 4.5 4.5 9.0 Flowing Agent Stearic Acid 1.5 1.5 1.5 3.0 Lubricant Sodium Stearyl 2.0 2.0 2.0 4.0 Lubricant Fumarate (PRUV) Total Weight 100.0 100.0 100.0 200.0 - In the pseudo-proportional formulations, the amount of ladostigil tartrate and mannitol remains constant, but the ratio between the two changes; the amount of the other excipients remains constant. The proportional formulation is double the formulation of the 25 mg pseudo-proportional formulation.
- These formulations proved to be stable at conditions of 30° C./60% RH and RT/60% RH, but change in tablet color occurred at accelerated conditions, specifically 40° C./75% RH after 1-2 months.
- In an attempt to increase stability, tablets were prepared according to the formulations in Table 2:
-
TABLE 2 Second Formulations Excipients Formulation (mg) O P Q R Ladostigil 32 32 32 32 Tartrate Mannitol USP 42 42 42 20 Starch 1500 20 20 20 40 SYLOID 244 2.5 2.5 2.5 4.5 (Colloidal Silicon Dioxide) Stearic Acid 1.5 1.5 1.5 1.5 PRUV (Sodium 0 2.0 0 2.0 stearyl fumarate) Talc 0 0 2.0 0 - Tablets using formulation O were manufactured using direct compression. On a small scale, the tablets using formulation O were manufactured without sticking problems. However, on a larger scale, and when other batches of ladostigil tartrate with different particle size distributions were used, there were sticking problems in the tableting process.
- As a result, formulations P, Q and R were manufactured using dry granulation, and using two different lubricants. This eliminated some of the sticking problems.
- The stability of formulations O, P, Q and R was tested at 40° C./75% RH for 3 months, and determined by the color of the tablets at 0, 1, 2 and 3 months, which was verified by an HPLC assay of total impurities. The results are shown in Table 3:
-
TABLE 3 Stability Profile of Second Formulations Formulation 0 months 1 month 2 months 3 months R Total 0.16 0.5 impurities (percent) Appearance Off-white Off-white/ Creamy- creamy-yellow brown Q Total 0.07 0.23 impurities (percent) Appearance White Off-white P Total 0.07 0.3 0.4 impurities (percent) Appearance White Off-white/ Yellow yellow O Total 0.07 0.15 0.23 0.29 impurities (percent) Appearance White Off-white Off-white Off-white - Formulation Q was the most stable, apparently due to the lack of sodium stearyl fumarate as a lubricant. Accordingly, optimization of double weight formulation Q was performed to increase compressibility and stability, and the results are shown in Table 4:
-
TABLE 4 Compressibility Profile of Third Formulations2 Ladostigil Starch Stearic For- Compress- Tartrate 1500 SYLOID acid Talc mulation ibility1 (mg) (mg) (mg) (mg) (mg) R1 2 64 40 5 3 4 S 1 64 40 5 3 8 T 5 64 40 5 6 4 U 5 64 40 5 6 8 V 1 64 40 5 3 W 5 64 40 5 3 X 5 64 40 9 4 8 Y 0.5 64 40 5 4 8 Z Can't 64 40 5 2 press AA 0-0.4 64 80 9 4 8 CC 0.2 64 80 5 4 8 1Compressibility was measured on a scale from 0 to 5, zero being most compressible and 5 being least compressible. The formulations graded 5 encountered severe sticking problems in the tableting process. 2In all formulations in Table 4, Mannitol USP was added as a filler in order to complete the tablet weight to 200 mg for each formulation. - Increasing the stearic acid levels to 8 mg/tablet (3% per tablet) increased the sticking problem. Thus, it was determined that 4 mg/tablet (2% per tablet) of stearic acid was the optimal amount.
- In addition, increasing the disintegrant amount, i.e., Starch 1500, helped compressibility.
- Different formulations were kept at 55° C. Stability was assessed by color changes (relative to unheated tablets) after 6 or 14 days, the results of which are shown in Table 5:
-
TABLE 5 Stability of Third Formulations1 Ste- For- Ladostigil aric mu- Tartrate Starch SYLOID acid Talc lation (mg) (mg) (mg) (mg) (mg) 6D 14D R1 64 40 5 3 4 White White BB 64 40 9 4 4 White White Y 64 40 5 4 8 White White CC 64 80 5 4 8 White White to off white X 64 40 9 4 8 White White to off white AA 64 80 9 4 8 White White to off white 1In the formulations of Table 5, Mannitol USP was added as a filler in order to complete the tablet weight to 200 mg for each formulation. - Formulations R1, Y, BB and CC were stable under accelerated conditions. A flow problem resulted, however, due to large variability in particle size distribution, resulting in a change in the crystallization method of ladostigil tartrate.
- The manufacturing process was changed from the dry granulation process to a wet-granulation process as a result of the flow problem with the active ingredient. Water and ethanol are the two most common agents used in wet granulation. Granulation experiments were first performed with water. The appearance of the formulations containing those granulates became creamy to brownish after 1 day at 55° C., which indicated that ladostigil tartrate was unstable in the presence of water. Moreover, ladostigil tartrate was found to be incompatible with ethanol. Therefore, granulation experiments based on the CC formulation were performed with isopropanol.
- Uniform, flowing granulates were obtained and tablets were compressed according to the two formulations in Table 6:
-
TABLE 6 Fourth Formulations A (mg) B (mg) Ladostigil Tartrate 64.0 64.0 Mannitol USP/BP 35 35 Starch 1500 80 80 Pregelainized starch SYLOID 244 (Silicon 4.5 — Dioxide) Polividone 30 (PVP) 12.5 12.5 Stearic acid 3 4 Talc 8 8 - Stability tests were performed on the two formulations in 40° C./75% RH stability conditions, the results of which are shown in Tables 7 and 8:
-
TABLE 7 Stability of Fourth Formulations Relative Retention Time Batch Time R-CAI CIONE 1.17 2.25-2.43 3.39-3.41 Total Appearance A Zero 0.1 * * * * 0.1 white 1 month 0.2 * * * * 0.2 off white 3 months 0.3 0.07 * 0.06 * 0.4 off white B Zero 0.08 * * * * 0.08 white 1 month 0.1 * 0.08 * * 0.2 white 2 months 0.2 * * * * 0.2 white 3 months 0.2 * * * * 0.2 white/off white 4 months 0.2 * * 0.09 * 0.3 white/off white 5 months 0.2 * * * 0.06 0.3 Beige/yellow * The number is listed only when the impurity peak is greater than or equal to 0.05. All units are in percent. R-CAI and CIONE are acronyms for the following impurities: Ethyl-methyl-carbamic acid 3-amino-indan-5-yl ester and Ethyl-methyl-carbamic acid 3-oxo-indan-5-yl ester, respectively. -
TABLE 8 Dissolution Profile of Fourth Formulations Batch No. Time (min) 15 30 45 A Zero 95 103 104 1 month 88 97 98 6 months 94 100 B Zero 96 96 1 month 97 99 2 months 94 96 3 months 94 96 4 months 94 96 5 months 95 96 6 months 93 93 All units are in percent. - These two formulations were found to be uniform and stable. All alternative formulations were within specifications under stress conditions (40° C./75% RH) and the color showed no change after 4 months.
- More binder (PVP) was later added in order to improve structure and flowing properties after granulation.
- Final formulations comprising different amounts of ladostigil tartrate are shown in Table 9:
-
TABLE 9 Final Formulations Tablet Tablet Tablet equivalent to equivalent to equivalent to 20 mg 50 mg 80 mg Excipient Ladostigil Ladostigil Ladostigil (mg) Tartrate base Tartrate base Tartrate base Function Ladostigil 25.6 64.0 102.4 Drug Tartrate Substance Mannitol 13.4 33.5 53.6 Filler USP/BP Pregelatinized 32.0 80.0 128.0 Disintegrant starch (starch 1500 NF) SYLOID 244 1.8 4.5 7.2 Disintegrant (Colloidal and flowing Silicon agent Dioxide) Polividone 30 7.2 18.0 28.8 Binder (PVP) Mannitol 120.0 — — Filler granulate Stearic acid 4.0 4.0 6.4 Lubricant Talc 8.0 8.0 12.8 Lubricant Isopropyl q.s. q.s. q.s. alcohol Total tablet 212.0 212.0 339.2 weight - Stability tests were performed on the final formulations at 30° C./65% RH. The tablets were packaged in aluminum silver/aluminum soft blister packs.
-
TABLE 10 Stability of Final Formulations Dose Time Total (mg) (months) R-CAI CIONE Impurities 20 0 0.06 <0.05 0.06 20 12 0.3 0.07 0.5 50 0 0.07 <0.02 0.07 50 12 0.3 0.08 0.5 80 0 0.07 <0.05 0.07 80 12 0.3 0.08 0.5 The impurities are listed in percent by weight. - Capsules were made from the excipients in Table 9. The capsules were determined to be stable at RT for 21 months, and at 30° C. for 12 months.
- Administration of Ladostigil Tartrate to Alzheimer's Disease Patients 8 patients, 7 female and 1 male, ages 62-81 with a median age of 68 and above with diagnosis of probable Alzheimer's disease according to DSM-IV (290.00 or 290.10) and NINCDS-ADRDA criteria were administered ladostigil tartrate as formulated in Table 9 according to the following schedule:
Week 1: 70 mg (50+20) once daily.
Week 2: 70 mg (50+20) twice daily.
Week 3-Week 9: 100 mg (50*2) twice daily. - 4 patients (3 male and 1 female) aged 70 to 84 years old were in the placebo group.
- Pharmacokinetic analysis was performed on Week 4 (maintenance analysis) and on Week 9 (termination analysis). At maintenance analysis (M), samples were collected pre-dose and at 0.25, 0.5, 1, 2, and 3 hours post-dose. At termination analysis (T), samples were collected pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, and hours post-dose.
-
TABLE 11 Patient Number 1 2 3 4 5 6 7 8 MAO (T) −55 −85 −98 −76 −89 −76 −54 −64 (%) DHPG −63 −86 ND ND >−79 −73 −30 −13 (T) (%) AUC (ng * hr/mL) ladostigil 314 589 1005 927 436 551 52 500 (M) ladostigil 246 2305 1449 482 398 901 118 350 (T) Cmax (nmol/mL) ladostigil 1.1 1.2 3.5 3.9 1.4 1.5 0.2 1.7 (M) ladostigil 0.7 3.8 3.9 1.6 1.0 2.5 0.4 1.3 (T) - Mean Cmax after dosing and mean Cmin (concentration at pre-dose) of ladostigil tartrate at maintenance analysis (M) and at termination analysis (T) were determined and are listed in Table 12, as well as half life (t1/2) at termination. The concentration measurements are expressed in nmol/ml and the t1/2 is expressed in terms of hours.
-
TABLE 12 Pharmacokinetic Analysis Analyte Cmin (M) Cmin (T) Cmax (M) Cmax (T) t1/2 Ladostigil 0.0164 0.0109 2.02 1.88 1.08 Tartrate - Monoamine oxidase B (“MAO-B”) inhibition in plasma samples from the aforementioned patients was determined at baseline and at termination analysis using liquid scintillation counting. The percent inhibition was calculated for each patient, and the mean percent inhibition was then determined to be 75% (standard deviation=16) at the termination analysis.
- Decrease of 3,4-dihydroxyphenylglycol (“DHPG”) in plasma is indicative of monoamine oxidase inhibition, especially in the brain. DHPG plasma concentrations were measured in 6 of the aforementioned patients at baseline and at termination analysis, using HPLC equipped with an electrochemical detector.
- The decrease in DHPG concentration in the six patients was determined. The average decrease in DHPG concentration was determined to be 57% with a standard deviation of 29.
- The data show that the analytes were present at pre-dose (which corresponds to 12 hours after the previous dose) both at maintenance and at termination analyses.
- There is evidence of significant MAO-B inhibition.
- Cholinesterase inhibition at pre-dose administration both at maintenance and at termination analyses was also evident.
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/211,721 US20110301234A1 (en) | 2005-02-24 | 2011-08-17 | Formulations of ladostigil tartrate |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65647705P | 2005-02-24 | 2005-02-24 | |
US11/361,379 US8022104B2 (en) | 2005-02-24 | 2006-02-24 | Formulations of ladostigil tartrate |
US13/211,721 US20110301234A1 (en) | 2005-02-24 | 2011-08-17 | Formulations of ladostigil tartrate |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/361,379 Continuation US8022104B2 (en) | 2005-02-24 | 2006-02-24 | Formulations of ladostigil tartrate |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110301234A1 true US20110301234A1 (en) | 2011-12-08 |
Family
ID=36927766
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/361,379 Expired - Fee Related US8022104B2 (en) | 2005-02-24 | 2006-02-24 | Formulations of ladostigil tartrate |
US13/211,721 Abandoned US20110301234A1 (en) | 2005-02-24 | 2011-08-17 | Formulations of ladostigil tartrate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/361,379 Expired - Fee Related US8022104B2 (en) | 2005-02-24 | 2006-02-24 | Formulations of ladostigil tartrate |
Country Status (7)
Country | Link |
---|---|
US (2) | US8022104B2 (en) |
EP (1) | EP1848417A1 (en) |
JP (1) | JP2008531594A (en) |
AU (1) | AU2006216509B8 (en) |
CA (1) | CA2600603A1 (en) |
IL (1) | IL185420A0 (en) |
WO (1) | WO2006091836A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1848417A1 (en) * | 2005-02-24 | 2007-10-31 | Teva Pharmaceutical Industries Ltd | Formulations of ladostigil tartrate |
US20070093549A1 (en) * | 2005-09-28 | 2007-04-26 | Judith Aronhime | Methods for preparation of ladostigil tartrate crystalline form A1 |
WO2007061717A2 (en) * | 2005-11-17 | 2007-05-31 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
CA2634166C (en) * | 2005-12-09 | 2016-03-29 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
US20070232691A1 (en) * | 2006-03-31 | 2007-10-04 | Tamar Goren | Use of ladostigil for the treatment of schizophrenia |
WO2012059920A1 (en) * | 2010-11-02 | 2012-05-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Ladostigil dosage regime |
CA2862984C (en) | 2012-02-12 | 2021-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Ladostigil therapy for immunomodulation |
WO2013182625A1 (en) * | 2012-06-08 | 2013-12-12 | Actavis Group Ptc Ehf | Pharmaceutical formulation with propargylamine compound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022104B2 (en) * | 2005-02-24 | 2011-09-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Formulations of ladostigil tartrate |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1534864A (en) * | 1919-12-19 | 1925-04-21 | Hazel Atlas Glass Co | Apparatus for tempering glassware |
US2026165A (en) * | 1934-08-01 | 1935-12-31 | Libbey Owens Ford Glass Co | Process and apparatus for producing case hardened glass |
US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
US4086263A (en) * | 1976-11-17 | 1978-04-25 | Ppg Industries, Inc. | Shipping rack having spacer strips attached thereto |
US4488192A (en) * | 1982-05-28 | 1984-12-11 | International Business Machines Corporation | Cooling arrangement for hermetically sealed disk files |
IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
DE69535315T2 (en) | 1994-01-10 | 2007-06-28 | Teva Pharmaceutical Industries Ltd. | 1-AMINOINDANDERIVATE AND COMPOSITIONS HEREVON |
FI100397B (en) * | 1995-10-24 | 1997-11-28 | Glassrobots Oy | Heat transfer method in glass sheet bending furnace and bending furnace |
EP0827489A1 (en) * | 1996-03-21 | 1998-03-11 | Peter Lisec | Process and plant for hardening glass plates |
FR2747112B1 (en) * | 1996-04-03 | 1998-05-07 | Commissariat Energie Atomique | DEVICE FOR TRANSPORTING FLAT OBJECTS AND METHOD FOR TRANSFERRING THESE OBJECTS BETWEEN SAID DEVICE AND A PROCESSING MACHINE |
EP0951284B1 (en) | 1996-12-18 | 2003-10-08 | Teva Pharmaceutical Industries, Ltd. | Phenylethylamine derivatives |
US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
HU229507B1 (en) * | 1996-12-18 | 2014-01-28 | Technion Res & Dev Foundation | 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them |
WO1998029119A1 (en) | 1996-12-30 | 1998-07-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JPH1179389A (en) * | 1997-09-16 | 1999-03-23 | Mitsui Eng & Shipbuild Co Ltd | Substrate glass inspection processing system |
JPH1179388A (en) * | 1997-09-16 | 1999-03-23 | Mitsui Eng & Shipbuild Co Ltd | Glass sheet handling device |
TW444275B (en) * | 1998-01-13 | 2001-07-01 | Toshiba Corp | Processing device, laser annealing device, laser annealing method, manufacturing device and substrate manufacturing device for panel display |
US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
AU2003219913A1 (en) | 2002-02-27 | 2003-09-09 | Teva Pharmaceutical Industries, Ltd. | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
WO2005051371A1 (en) | 2003-11-25 | 2005-06-09 | Technion Research & Development Foundation Ltd. | Compositions and methods for treatment of cardiovascular disorders and diseases |
AU2005244867A1 (en) | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
AU2006216695A1 (en) | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof |
EP1888056A4 (en) | 2005-06-01 | 2008-09-03 | Teva Pharma | Use of ladostigil for the treatment of multiple sclerosis |
US20070135518A1 (en) | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
CA2634166C (en) | 2005-12-09 | 2016-03-29 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
US20070232691A1 (en) | 2006-03-31 | 2007-10-04 | Tamar Goren | Use of ladostigil for the treatment of schizophrenia |
-
2006
- 2006-02-24 EP EP06721040A patent/EP1848417A1/en not_active Withdrawn
- 2006-02-24 CA CA002600603A patent/CA2600603A1/en not_active Abandoned
- 2006-02-24 AU AU2006216509A patent/AU2006216509B8/en not_active Ceased
- 2006-02-24 US US11/361,379 patent/US8022104B2/en not_active Expired - Fee Related
- 2006-02-24 JP JP2007557195A patent/JP2008531594A/en not_active Withdrawn
- 2006-02-24 WO PCT/US2006/006636 patent/WO2006091836A1/en active Application Filing
-
2007
- 2007-08-21 IL IL185420A patent/IL185420A0/en unknown
-
2011
- 2011-08-17 US US13/211,721 patent/US20110301234A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022104B2 (en) * | 2005-02-24 | 2011-09-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Formulations of ladostigil tartrate |
Also Published As
Publication number | Publication date |
---|---|
AU2006216509A1 (en) | 2006-08-31 |
US20060189685A1 (en) | 2006-08-24 |
WO2006091836A8 (en) | 2007-04-12 |
US8022104B2 (en) | 2011-09-20 |
AU2006216509B8 (en) | 2012-11-01 |
IL185420A0 (en) | 2008-08-07 |
CA2600603A1 (en) | 2006-08-31 |
WO2006091836A1 (en) | 2006-08-31 |
EP1848417A1 (en) | 2007-10-31 |
WO2006091836A9 (en) | 2006-10-26 |
AU2006216509B2 (en) | 2012-05-31 |
JP2008531594A (en) | 2008-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110301234A1 (en) | Formulations of ladostigil tartrate | |
US10441585B2 (en) | Formulations containing nalbuphine and uses thereof | |
EP1892233A1 (en) | New salts of the active component rasagiline | |
US20070172521A1 (en) | Levetiracetam formulations and methods for their manufacture | |
US20060222703A1 (en) | Pharmaceutical composition and preparation method thereof | |
US20100255099A1 (en) | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders | |
US20180071230A1 (en) | Formulations, salts and polymorphs of transnorsertraline and uses thereof | |
US20230157947A1 (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
US20100292341A1 (en) | Quick dissolve compositions of memantine hydrochloride | |
US7955620B2 (en) | Stable oral composition | |
US8124640B2 (en) | Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof | |
WO2013091704A1 (en) | Pharmaceutical composition comprising fingolimod | |
US20100086590A1 (en) | Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof | |
US20120122993A1 (en) | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate | |
US9271951B2 (en) | Levothyroxine formulation with acacia | |
WO2013190151A1 (en) | Pharmaceutical composition comprising fingolimod | |
JP4078206B2 (en) | Malbinated salt of terbinafine | |
WO2013168032A1 (en) | Pharmaceutical compositions comprising rasagiline | |
AU2012241189A1 (en) | Fast Dissolving Solid Dosage Form | |
EP2996681B1 (en) | Pharmaceutical composition comprising fingolimod | |
CN114945362A (en) | Dichlorofenamide compositions and methods of use | |
US20220175774A1 (en) | Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor | |
US20210275546A1 (en) | High drug load solid oral dosage forms of dexamethasone | |
WO2012172413A1 (en) | Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof | |
WO2017114597A1 (en) | Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES, LTD.;REEL/FRAME:028474/0786 Effective date: 20091122 Owner name: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (60%);REEL/FRAME:028474/0821 Effective date: 20110811 Owner name: TEVA PHARMACEUTICAL INDUSTRIES, LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LICHT, DANIELLA;LOVINGER, IOANA;CACIULARU, FANNY;AND OTHERS;SIGNING DATES FROM 20060402 TO 20060409;REEL/FRAME:028474/0733 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |